Most material SEC filings — July 15, 2026

SemiLEDs Corp filed an 8-K on July 15, 2026 reporting Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing does not disclose specific reasons, counterparties, dollar amounts, or remediation details in the provided text. This represents a potential loss of public market listing status for the company.

On July 10, 2026, SPAR Group received notice regarding failure to satisfy continued listing standards or delisting from its exchange. The 8-K filing reports Item 3.01 (Notice of Delisting or Failure to Satisfy Continued Listing Rule) and Item 5.07 (Matters submitted to vote), indicating potential loss of exchange listing. No specific financial amounts, remediation plans, or detailed circumstances are disclosed in the filing metadata provided.

Triller Group Inc. filed an 8-K on July 15, 2026 reporting Item 3.01 (Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard). The filing indicates the company has failed to maintain continued listing standards on its exchange. No specific counterparties, dollar amounts, or remediation timeline are disclosed in the filing header.

Q32 Bio Inc. (market cap ~$10.4M) executed an underwritten public offering on July 14-16, 2026, issuing 6,027,399 common shares at $18.25/share and 4,931,506 pre-funded warrants at $18.2499/warrant, with underwriters Morgan Stanley, Jefferies, Cantor Fitzgerald, and Oppenheimer. Underwriters have a 30-day option to purchase up to 1,643,835 additional shares at $17.1550/share. Gross proceeds before expenses approximately $110M from primary offering alone.

Glucotrack, Inc. (public market value ~$5.4M) agreed to merge with Lokahi Therapeutics, Inc. (private) via a forward triangular merger. Lokahi shareholders receive 90% of post-Closing equity (on fully diluted basis, including Bridge Shares and PIPE Shares, capped at 10% floor for Glucotrack existing shareholders) as Acquiror Common Stock and Series A Convertible Preferred Stock (~100:1 conversion ratio). Lokahi's $7M promissory note is assumed by the Company. Up to $30M private placement targeting minimum $10M at PIPE Initial Closing. Operating Business ring-fenced in subsidiary; Lokahi operates Surviving Corporation during 12-month interim period.

Celcuity announced FDA approval of REVTORPYK (gedatolisib) on July 14, 2026, for HR+/HER2-, PIK3CA wild-type locally advanced or metastatic breast cancer. In Phase 3 VIKTORIA-1 trial, REVTORPYK+palbociclib+fulvestrant reduced progression/death risk by 76% (median PFS 9.3 vs 2.0 months); REVTORPYK+fulvestrant reduced risk by 67% (median PFS 7.4 vs 2.0 months). Commercial launch planned late Q3 2026; supplemental NDA for PIK3CA-mutant cohort expected Q3 2026.

BayFirst Financial Corp. announced a restatement of audited financials for 2024, 2025, and Q1 2026 due to understatement of loan loss provisions and overstatement of net interest income totaling $4.9M in prior-period errors ($2.8M deferred origination costs, $2.1M accrued interest on defaulted loans). Additionally, the company took $37.0M in adjustments to SBA loan valuations, $1.5M impairment on non-marketable equity, and $1.6M write-down on USDA loan premiums—all related to an asset resolution plan. Net income restated from $12.6M to $11.4M (2024); net loss worsened from $22.9M to $24.2M (2025); Q1 2026 loss worsened from $5.7M to $5.9M. Amendments to 10-K and 10-Q due by August 12, 2026.

SemiLEDs reported Q3 FY2026 (ended May 31, 2026) revenue of $9.1 million versus $1.1 million in Q2, driven by increased buy-sell equipment purchase orders. GAAP net income was $1.5 million ($0.18 per diluted share) versus a $603K loss in Q2. Gross margin expanded to 27% from 1%, operating margin to 16% from −79%. Cash rose to $6.0 million from $4.0 million. The company has 8.3 million diluted shares outstanding and ~$5.7M market cap.

Worthington Steel (NYSE: WS), which already owns ~62% of German steel processor Kloeckner Co SE following completion of its public takeover offer on June 3, 2026, has opened a delisting tender offer for remaining outstanding shares at EUR 11.00 per share. The acceptance period runs July 15–August 12, 2026, with no closing conditions or minimum acceptance threshold. Following delisting from Frankfurt Stock Exchange, Kloeckner shares will lose trading liquidity.

Celadon Partners SPV 35 Limited (Parent) agreed to merge with Senti Biosciences Holdings, Inc. via merger sub into Midco, with stockholders receiving CVRs (contingent value rights) tied to future milestone achievements. Celadon holders already beneficially own ~54.6% of outstanding shares (9.78M shares, warrants, and $10M convertible notes). Deal requires majority stockholder approval and majority-of-minority approval from non-affiliated shareholders.

Between December 22, 2025 and February 20, 2026, reporting persons affiliated with American Industrial Partners (Lightship Capital III LP, AIPCF VIII funds) purchased approximately 3,900,000 shares of Rayonier Advanced Materials common stock in open-market transactions at prices ranging from $5.74 to $8.41 per share, totaling approximately $30.2M. This represents a material accumulation by a significant shareholder.

Eos Energy announced preliminary Q2 2026 results: revenue of $68–69M (highest quarterly ever, 3x YoY growth); gross margin loss of 69–73% due to Battery Line 2 ramp-up costs and expansion from one to two production lines; backlog of ~$807M (company record, +25% sequentially); cash of ~$364M. H1 2026 revenue exceeded all of 2025 revenue. Battery Line 2 commenced commercial production mid-June with better yields and cycle times than Line 1; bipolar automation line 50% complete, full commissioning expected July 2026.

Kairos Pharma announced interim Phase 1 safety data for ENV-105 (carotuximab) combined with osimertinib in EGFR-mutated NSCLC: 13 patients treated with no Grade 3+ adverse events observed. ENV-105 targets CD105, a resistance driver in osimertinib-resistant patients. The $10 billion EGFR-NSCLC market has no approved agent to reverse osimertinib resistance; this trial advances toward Phase 2 dose recommendation.

Veradermics announced positive topline results from Study 207, a Phase 2 open-label trial of VDPHL01 (extended-release oral minoxidil) in 28 female patients with mild-to-moderate pattern hair loss. Primary endpoints were met: 88.9% (once-daily) and 90.0% (twice-daily) of participants reported 'improved' or 'much improved' hair coverage at Month 6; mean non-vellus hair count increased 22.7 hairs/cm² (once-daily) and 23.3 hairs/cm² (twice-daily). Safety was favorable—no serious adverse events, no cardiac-origin adverse events of special interest. Company expects registration-directed Phase 2/3 Study 306 topline data in 1H 2027.

Arts Way Manufacturing secured a $516,971 promissory note from Bank Midwest (Armstrong Branch) dated October 1, 2025, maturing October 5, 2035. The loan carries a fixed 7.250% interest rate for the first 60 months ($6,102.36/month), then converts to variable rate (5-Year Treasury Index + 3.25% margin, floor 5.00%, ceiling market cap) for remaining 119 months. Proceeds designated for Armstrong Roof project; secured by real estate mortgage dated 9/28/2017 and other collateral.

Lakewood-Amedex Biotherapeutics (total assets ~$196K) disclosed an investor presentation dated July 15, 2026, highlighting its lead candidate Nu-3, a topical antimicrobial gel for infected diabetic foot ulcers. The company announced Phase 2a/2b clinical trial initiation with planned enrollment commencing in 2Q26, drug manufacturing completion by 3Q26, trial completion by 4Q26, and topline results expected 4Q26/1Q27. No counterparties, financing amounts, or equity transactions are specified in the filing.

On April 29, 2026, authID closed a private placement of ~$4.165M principal in Senior Secured Debentures (maturing October 2026, no interest) plus warrants and fee shares to accredited investors. This S-1 registers for resale 4,637,852 shares: 4,065,000 warrant shares (exercise price $1.50, 5-year term) and 572,852 fee shares. The warrants represent 100% of capital invested; fee shares equal 15% of invested amount. Nasdaq Rule 5635 caps issuable shares at 19.99% of pre-financing outstanding shares without stockholder approval. Company received ~$3.5M net proceeds after expenses and will receive additional cash only if warrants are exercised (potential $6.1M gross if all exercised for cash).

First Hawaiian, Inc. (Delaware corp., $3.1B market cap) agreed to acquire TriCo Bancshares (California corp.) in an all-stock merger dated July 12, 2026. The exchange ratio is 2.095 shares of First Hawaiian Common Stock per share of TriCo Common Stock. As of July 10, 2026, TriCo had 31,965,507 shares outstanding. The transaction involves: (1) Merger Sub merging into TriCo with TriCo surviving; (2) TriCo immediately merging into First Hawaiian; (3) TriCo Bank merging into First Hawaiian Bank. Regulatory approvals from Federal Reserve, FDIC, Hawaii DFI, and California DFPI are required. Both companies' boards approved; shareholder votes required.

Cathael Precision designated up to 3,470 shares of Series C-3 Convertible Preferred Stock with $1,000 stated value per share and $0.632 conversion price (subject to a $0.35 floor). The preferred stock has liquidation preference senior to common stock, conversion rights, and broad anti-dilution protections. The designation references a February 6, 2026 securities purchase agreement and companion registration rights agreement; holders receive majority voting control over material corporate actions once 33.33% of shares are outstanding.

On July 10, 2026, GameSquare granted 50,000 RSUs to Amaree Vichairattanawong (vesting immediately), 1,195,712 stock options to Justin Kenna at $0.31/share (803,570 vesting immediately, 392,142 on July 10, 2027, expiring July 9, 2031), and 301,249 stock options to Mike Munoz at $0.31/share (188,280 vesting immediately, 112,969 on July 10, 2027, expiring July 9, 2031). Total option grants: ~1.5M shares at $0.31 exercise price.

Fractyl Health announced positive one-year results from the REMAIN-1 Midpoint Cohort (N=45 randomized, 29 Revita vs 16 sham). In patients receiving complete duodenal ablation (≥14 cm) with high GLP-1 run-in weight loss (≥17.5%), Revita maintained 84% of GLP-1-induced weight loss versus 46% in sham controls (4.1% vs 13.5% least-squares mean regain). In the full cohort, Revita reduced weight regain by 40% versus sham. Safety profile was excellent: no device-related serious adverse events, treatment-emergent adverse event rates matched sham (24% vs 25%). Company anticipates pivotal topline 6-month data in early Q4 2026 and potential FDA De Novo submission in late Q4 2026. Cash position: $63M at end of Q1 2026 with runway into early 2027.

Conagra Brands (fiscal year ended May 31, 2026) reported $2.9B in goodwill and brand impairments (primarily Refrigerated Frozen segment), driving a $4.00 diluted loss per share. Reported FY26 net sales declined 2.9% to $11.3B; organic sales fell 0.4%. Adjusted EPS of $1.72 (vs. $2.30 prior year). New CEO John Brase announced dividend cut from $0.70 annualized to $0.35 (50% reduction). FY27 guidance: organic sales decline (3)% to (1)%, adjusted operating margin 10.0–10.5%, adjusted EPS $1.40–$1.50. Net leverage ratio 3.83x (up from target); company cited margin compression, cost inflation, volume declines, and depressed share price as drivers of impairment.

10% owner Aqua Capital, Ltd. (ENR) bought 100K shares (~$2.0M) on the open market (1.3% of holdings). Open-market insider purchase — historically a bullish signal.

FEI reported FY2026 revenue of $63.2M (down 10% YoY) but funded backlog surged to $111M (up 59% YoY, 34% sequentially). Company established three-year targets: minimum $150M revenue by FY2029 (34% CAGR), 50% gross margin, and 30% operating margin. FY2026 included $3.8M inventory write-down from FEI-Elcom restructuring and transformational hiring/manufacturing investments; on a GAAP basis, reported operating loss of $3.0M for full year, but adjusted operating income of $2.7M excluding non-recurring items.

First Hawaiian, Inc. (Parent) agreed to acquire TriCo Bancshares (Company) via merger agreement dated July 12, 2026, with Company shareholders receiving 2.095 shares of Parent Common Stock per Company share held (Exchange Ratio). As of July 10, 2026, Company had 31,965,507 outstanding shares; Parent had 121,676,249 outstanding shares. Transaction includes Second Step Merger of surviving company into Parent, followed by bank merger of Tri Counties Bank (Company subsidiary) into First Hawaiian Bank (Parent subsidiary). Company Shareholder Approval (two-thirds vote) and Parent Stockholder Approval (majority vote) required. Regulatory approvals from Federal Reserve, FDIC, Hawaii Division of Financial Institutions, and California Department of Financial Protection and Innovation needed.

RxSight announced a leadership transition effective July 20, 2026: Aziz Mottiwala, former Chief Commercial Officer at Tarsus Pharmaceuticals and Opiant Pharmaceuticals, becomes President and CEO, replacing Ron Kurtz, M.D., the founder-leader who moves to Chief Medical Officer and resigns from the Board. Mottiwala brings 10+ years of eye care commercial experience from Allergan. No financial guidance was updated. Board composition changes with Mottiwala joining the Board as Kurtz departs it.

10% owner Skaff Michael C (VVOS) bought 5.5M shares (~$3.2M) on the open market (67% of holdings). Open-market insider purchase — historically a bullish signal.

On June 4, 2026, Howard Hughes Holdings Inc. completed its acquisition of Vantage Group Holdings Ltd. for $2.1 billion in cash. HHH also issued $1.0 billion of redeemable preferred stock (non-interest-bearing, non-voting) to Pershing Square Holdings Ltd. Vantage is a Bermuda-domiciled property, casualty, and specialty reinsurer with 2025 net earned premiums of $1,035.4 million and net income of $197.0 million; as of March 31, 2026, Vantage had total assets of $5.2 billion and total equity of $1.44 billion.

President Kang Andrew Kai (BOT) bought 272K shares (~$10.0M) on the open market (12% of holdings). Open-market insider purchase — historically a bullish signal.

Crescent Biopharma priced an underwritten public offering of 8,094,793 ordinary shares at $14.50/share and 525,897 pre-funded warrants at $14.499/warrant, with Jefferies and TD Securities as lead underwriters. The offering also grants underwriters an option to purchase up to 1,293,103 additional shares at $13.63/share. Gross proceeds approximately $117.3M before underwriting discounts; net proceeds used for general corporate purposes as described in prospectus.

Axsome announced FDA acceptance of its New Drug Application (NDA) for AXS-12 (reboxetine) to treat cataplexy in narcolepsy, with a PDUFA target action date of May 1, 2027. The FDA indicated it does not plan to hold an advisory committee meeting. AXS-12 has orphan drug designation; cataplexy affects ~70% of narcolepsy patients. No specific commercial or financial terms were disclosed in the filing.

On July 13, 2026, Genasys Inc. executed a Third Amendment to its Term Loan and Security Agreement with Cantor Fitzgerald Securities (Agent) and lenders including Whitebox funds and Pandora Select Partners. The amendment extends the maturity date of the $15,206,812.50 Closing Date Term Loan from July 13, 2026 to July 13, 2027 (one year extension). The First Amendment Term Loan ($4M) has been paid in full. Key changes: (1) after July 13, 2026, prepayments trigger a Minimum Return Amount instead of a 1% premium; (2) liquidity covenant waived July 13-20, 2026; (3) default on Section 7.18 (minimum liquidity) waived retroactively; (4) all representations, warranties, and covenants reaffirmed; (5) Guarantors (Genasys Puerto Rico LLC, Evertel Technologies LLC, ZoneHaven LLC) remain liable. No new financing was advanced.

Plumas Bancorp reported Q2 2026 net income of $9.9 million ($1.43 per diluted share), up 57.6% from $6.3 million ($1.05 per share) in Q2 2025. The July 1, 2025 acquisition of Cornerstone Community Bank added $658 million in assets, $478 million in loans, and $580 million in deposits. For H1 2026, net income reached $19.7 million ($2.79 diluted EPS), up 46.1% from $13.5 million ($2.25 diluted EPS) in H1 2025. Net interest income surged 39.3% to $51.1 million in H1 2026 from $36.7 million in H1 2025; total assets grew 39.9% to $2.28 billion; total equity rose 40.9% to $272 million.

Sprout Social announced a reduction of approximately 20% of its workforce effective immediately. The company is providing severance including 12 weeks of base salary plus one week per year of tenure, six months of fully paid healthcare (US), acceleration of 90 days of vesting equity, and three months of outplacement support. No specific dollar amount or headcount provided; rationale cited is industry/software market changes requiring operational restructuring.

Rekor reported Q2 2026 preliminary results: $12.6M revenue (22% sequential, 2% YoY growth), 55% adjusted gross margin, $1.3M adjusted EBITDA loss (78% improvement YoY), and $10M cash. Company completed ~20% headcount reduction and expects $7.5M+ in annual cost savings. Management projects profitability on adjusted EBITDA basis in H2 2026 and launched Go-Secure.Video authentication technology with potential commercial partnerships in Q3 2026.

United Airlines reported Q2 2026 diluted EPS of $2.46 ($1.99 adjusted) on $17.7B revenue (+16% YoY), exceeding expectations despite a $2.3B fuel cost increase (84% YoY). The company raised full-year 2026 adjusted EPS guidance to $9.00–$11.00 and raised Q3 2026 guidance to $2.50–$3.50. It raised $3.7B in new liquidity, prepaid ~$1B of higher-cost debt, and expects to achieve investment-grade rating in 2026. Starlink is now on 450 aircraft with ~1,000 planned by year-end.

AEON Biopharma entered into an underwriting agreement with Lake Street Capital Markets on July 13, 2026, to sell 17.85M shares of Class A common stock at $0.3221/share, plus 24.84M pre-funded warrants, 42.69M two-year milestone warrants ($0.3221 exercise), and 42.69M five-year milestone warrants ($0.3704 exercise), with a 15% overallotment option. The firm securities have a combined purchase price of $0.29953 per share plus warrants. Closing scheduled for July 15, 2026. Lake Street Capital Markets and Laidlaw Company (UK) Ltd are underwriters.

John C. Roche, 62, will retire as President and CEO on December 31, 2026, after 40 years in insurance and 20 years at Hanover (joined 2006, CEO since 2017). Richard W. Lavey, 59, currently Chief Operating Officer and President of Hanover Agency Markets (22-year tenure since 2004), has been appointed CEO-elect and will transition into the role. Lavey oversees core commercial and personal lines representing 75% of Hanover's $7B gross premiums written. No severance amounts, equity acceleration, or financial terms disclosed.

Home BancShares (HOMB) completed its acquisition of Mountain Commerce Bancorp during Q2 2026. The deal added ~$1.47 billion in loans (net of purchase discounts) and $921 million in interest-bearing deposits. HOMB issued $146 million in common stock to Mountain Commerce shareholders. Despite $12.7 million in merger-related expenses, adjusted net income reached a record $128.1 million (up 8.4% QoQ), total assets grew to $24.71 billion (from $23.20 billion), and adjusted PPNR hit a record $171.2 million. Book value per share increased to $22.68 from $22.15.